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ScienceDirectAll cancers originate from a single cell that starts to behave
abnormally due to the acquired somatic mutations in its
genome. Until recently, the knowledge of the mutational
processes that cause these somatic mutations has been very
limited. Recent advances in sequencing technologies and the
development of novel mathematical approaches have allowed
deciphering the patterns of somatic mutations caused by
different mutational processes. Here, we summarize our
current understanding of mutational patterns and mutational
signatures in light of both the somatic cell paradigm of cancer
research and the recent developments in the field of cancer
genomics.
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Introduction
Long before the discovery of the double helix [1], it was
well established that ultraviolet light (UV) can cause
tumours of the skin [2]. While the mechanism was unclear
at this time, it was hypothesized that successive doses of
UV radiation result in accelerating the relative rate of cell
proliferation [3]. The paradigm shifting discovery that the
genetic material is contained within a deoxyribonucleic
acid led to many studies in the late 1950s and throughout
the 1960s examining how organisms protect their DNA
from endogenous and exogenous mutations, and a focus
was given to ultraviolet induced mutations (reviewed in
Ref. [4]). It was established that exposure to UV light can
lead to the formation of dimers of any two adjacent
pyrimidine bases on the same DNA strand with a
Open access under CC BY license.Current Opinion in Genetics & Development 2014, 24:52–60 preference for thymine–thymine dimers [4]. It was
further shown that UV irradiation damage predominantly
results in cytosine to thymine or cytosine–cytosine to
thymine–thymine changes, preferentially occurring at
these pyrimidine dimers (i.e. C > T or CC > TT DNA
mutations at dipyrimidine sites) [5,6]. This was the first
detailed characterization of the pattern of DNA changes
occurring due to the activity of an exogenous mutagen
and, as such, the very first description of a signature of a
mutational process.
While these early studies established the mutational
signature of UV light, it was unclear whether UV
induced mutations are present and involved in the
neoplastic expansion of human cancers. The develop-
ment of the DNA sequencing technique with chain-
terminating inhibitors by Sanger et al. [7] allowed rapid
examination of the genetic material contained in cancer
cells. In the early 1990s, two studies sequenced exons
of the gene TP53 [8,9] from several patients and
provided experimental evidence that aflatoxin and
UV light leave distinct patterns (consistent with the
ones observed in experimental systems) of DNA
mutations respectively in hepatocellular and squa-
mous-cell carcinomas. These studies confirmed that
the mutational signatures of carcinogens are left as
‘evidence’ in the genomes of cancer cells [10] thus
spawning research which first examined the mutations
across TP53 and later across multiple genes and even
whole cancer genomes in order to provide a better
understanding of the mutational processes involved
in human carcinogenesis.
Mutational patterns of TP53
Multiple independent studies used Sanger sequencing
of some (or all) exons of a cancer gene to provide clues
to the aetiology of both endogenous and exogenous
factors of human carcinogenesis. TP53 was usually
selected for this analysis due to its high prevalence
of somatic mutations in almost all tumour classes [11].
Commonly, each of these studies involved multiple
samples of a cancer type that were examined for
somatic mutations in TP53 (studies reviewed in Refs.
[11,12,13]). The TP53 somatic mutations were aggre-
gated, their spectrum was reported as specific for the
given cancer type, and this spectrum was then com-
pared to mutations generated experimentally in in vitro
or in vivo systems [11,13]. It should be noted that the
mutational spectra of other genes, albeit rarely, were
also used for such analysis [14].www.sciencedirect.com
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of the TP53 spectra across different cancer types, which
allowed associating some patterns of mutation to known
carcinogens. Here, we provide a brief summary of some of
the more important findings while details could be found
in Refs. [11,12,13]. The TP53 spectrum of skin carci-
nomas exhibited C > T and CC > TT mutations at
dipyrimidines (all substitutions and dinucleotide substi-
tutions are referred to by the pyrimidine(s) of the mutated
Watson-Crick base pair). This was consistent with the in
vitro described mutational signature of UV light. The
TP53 mutational spectrum derived from lung cancers in
tobacco smokers was overwhelmed by C > A substi-
tutions, which coincided with the class of mutation pro-
duced experimentally as a result of bulky adduct
formation by tobacco carcinogens on guanine [15]. In
other tobacco associated cancers, such as oesophageal
and head and neck tumours, C > A mutations (while still
ubiquitous) were less common while there was a signifi-
cant increase of T > C mutations. Interestingly, in both
smokers and non-smokers, C > T and C > G mutations
at non-CpG sites were elevated when compared to all
other cancer types, with bladder tumours harbouring the
most C > G mutations [11]. Additionally, it was demon-
strated that C > A transversions were common in hepa-
tocellular cancers and these mutations were believed to
be associated with aflatoxin, a known carcinogen com-
monly found in food from southern Africa and Asia [16].
Lastly, all cancer types harboured at least some C > T
mutations at CpG dinucleotides (mutated base under-
lined), a process attributed to the normal cellular event of
deamination of 5-methylcytosine [11].
The analyses of TP53 spectra were the first attempts to
bridge the gap between molecular cancer genetics and
epidemiology [17]. The large number of studies examin-
ing TP53 spectra required a computational resource to
facilitate and retrieve the already identified somatic
mutations. At first these data were managed by the
researchers that were generating it but in 1994 the Inter-
national Agency for Research on Cancer (IARC) started to
maintain a database while providing a free access to it
[17]. The first release of the IARC TP53 database con-
tained 3 000 somatic mutations [18] while the most
recent version (R16) released in November of 2012,
which can be found at http://p53.iarc.fr/, contains almost
30 000 somatic mutations in TP53.
Though extremely informative, the data gathered from
single gene studies have significant limitations. In these
studies, the spectrum of a cancer type is reported by
aggregating mutations from multiple samples. This may
be adequate when a single mutational process generates
the majority of mutations in the particular cancer (e.g. UV
light is the predominant mutational process in melanoma
[19]). However, usually multiple mutational processes
are operative in a single cancer sample, and combiningwww.sciencedirect.com their mutations generates a mixed composition of the
patterns of somatic mutations. In most cases, reporting
this jumbled spectrum is uninformative for the diversity
of mutational processes operative in a single cancer type
or in a single cancer sample [20]. Moreover, the
examined TP53 exons are both under selection and also
have a specific nucleotide sequence. This affects the
opportunity for observing a somatic mutation and as such
the reported spectrum can be a reflection of the processes
of selection and/or the nucleotide architecture of the
TP53 gene in addition to the processes of mutation
[21,22].
Two studies tried to overcome some of the single gene
limitations by leveraging a targeted capillary sequencing
approach of large number of genes. A survey of the 518
protein kinase genes in 25 human breast cancer samples
revealed 92 somatic mutations (90 substitutions and 2
indels) in which C > T transitions and C > G transver-
sions preceded by thymine (i.e. C > T and C > G at
TpC, mutated base is underlined) occurred with a higher
than expected frequency [23]. This survey was later
expanded to 210 cancer samples and it revealed more
than 1 000 somatic mutations with significant variations in
their patterns across the examined twelve cancer types
[24]. Only a small fraction of the mutations reported in
these screens are likely to be affected by selection [25],
thus indicating that the observed mutational patterns
reflect the operative mutational processes in the analyzed
samples and not the processes of negative or positive
selection.
Mutational patterns identified in next
generation sequencing data
The development of second-generation sequencing tech-
nologies allowed examination of cancer exomes (i.e. the
combined protein coding exons) and even whole cancer
genomes. Sequencing cancer exomes has been generally
preferred as the majority of known cancer-causing driver
somatic substitutions, indels, and copy number changes
(although generally not rearrangements) [21] are located
in protein coding genes. As the nucleotide sequence of
protein coding genes is 1% of the whole genome,
analysis of exomes is considered an advantageous and
cost effective methodology for discovering the genes
involved in neoplastic development. As a result, many
studies have focused predominantly on the generation
and analysis of exome sequences [26].
Early next generation sequencing studies started reveal-
ing patterns of somatic substitutions in different cancer
types. In 2010, two back-to-back studies in Nature
reported the patterns of somatic mutations in a malignant
melanoma [27] and small cell lung carcinoma [28]. As
expected, a strong signature of tobacco carcinogens was
found in the genome of the lung cancer, while the
mutational signature of ultraviolet light overwhelmedCurrent Opinion in Genetics & Development 2014, 24:52–60
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value of whole genome sequencing for evaluating signa-
tures of mutational processes by providing greater resol-
ution and mechanistic insight into mutational signatures
due to known carcinogens, for example through the
identification of a lower prevalence of mutations over
the footprints of genes.
Multiple independent studies and international consor-
tiums started sequencing large numbers of samples from
both cancer genomes and exomes [26]. An integrated
genomic characterization was reported for many different
cancer types including: acute lymphoblast leukemia [29–
31], acute myeloid leukemia [32], breast cancer
[33,34,35], chronic lymphocytic leukemia [36,37], color-
ectal cancer [38,39], oesophageal cancer [40], glioblas-
toma [41], cancers of the head and neck [42,43], kidney
cancer [44–46], liver cancer [47,48], lung cancer [49–54],
lymphomas [55,56], melanoma [57–60], multiple myel-
oma [61], ovarian cancer [62], pancreatic cancer [63,64],
prostate cancer [65–68], stomach cancer [69–71], uterine
cancer [72], and several different types of pediatric
tumours [73–79]. While these studies focused on the
identification of novel cancer genes, mutational spectra
were usually reported for each of the examined samples
and some studies even tried to associate certain types of
somatic mutations with the activity of mutagens or the
failure of DNA repair mechanisms. A brief summary of
the mutational patterns identified in these cancer geno-
mics studies is provided in the next paragraph.
In lung cancer, comparison between tobacco smokers and
non-smokers revealed that smokers have on average 10-
fold increase in the burden of somatic mutations in their
cancer genomes [50,51]. Consistent with the experimen-
tal evidence for tobacco carcinogens, this elevation is
mainly due to the increase of the number of C > A
transversions [15]. Examination of the cancer genomes
of melanomas confirmed that the majority of mutations
are C > T and CC > TT at dipyrimidines in the ultra-
violet-associated tumours, while acral melanomas exhibit
predominantly C > T transitions at CpG sites [59,60]. In
glioblastoma multiforme, it was demonstrated that treat-
ment with an alkylating agent, such as temozolomide,
significantly elevates the numbers of somatic mutations
and results in a distinct mutational pattern of C > T
transitions [41]. In chronic lymphocytic leukemia, it
was observed that samples with mutations in the immu-
noglobulin genes have a higher proportion of T > G
transversions [36]. This mutational pattern and its
immediate sequencing context are consistent with the
activity of the error-prone polymerase h during somatic
hypermutation [36,80]. In endometrial and colorectal
tumours, a set of ultra-hypermutators with increased
mutational frequency of transversions was associated with
somatic mutations in polymerase e [44,72]. Microsatellite
unstable gastric cancer were observed to have a higherCurrent Opinion in Genetics & Development 2014, 24:52–60 mutation prevalence of both C > T transitions and C > A
transversions [71]. Examining the cancer exomes of
patients with urothelial carcinoma (of the upper urinary
tract) revealed a large number of somatic mutations with
an unique pattern of T > A transversions predominately
located at CpTpG sites and possessing a very strong
transcription strand bias [81]. This pattern of mutations
was associated with exposure to aristolochic acid. In
oesophageal cancer, a high prevalence of T > G transver-
sions was observed [40] while certain breast cancer gen-
omes were found to be overwhelmed with C > T and
C > G mutations at TpC sites [35].
These next generation sequencing studies provided an
unbiased look into the patterns of DNA changes across
cancer genomes. While they resolved some of the
previous limitations from TP53 studies (mostly by exam-
ining large portions of the human genome which are
usually not under selection and which have a nucleotide
context that is representative of the whole human gen-
ome) they still did not address the important issue of
examining mixtures of mutations generated by different
mutational processes.
Mutational signatures derived from patterns
of somatic mutations
The somatic mutations in a cancer genome are the
cumulative result of the mutational processes that have
been operative since the very first division of the ferti-
lized egg, from which the cancer cell was derived [21,22].
Each of these mutations was caused by the activity of
endogenous and/or exogenous mutational processes with
different strengths (Figure 1). Some of these processes
have been active throughout the whole lifetime of the
cancer patient while others have been sporadically trig-
gered, for example, due to lifestyle choices (Figure 1).
While examining patterns of somatic mutations can pro-
vide an indication of the aetiology of the operative
mutational processes, it does not allow deciphering the
individual mutational signatures that are operative in
each sample as usually the pattern of a sequenced cancer
genome does not resemble any of the operative muta-
tional processes (Figure 1).
Recently, a theoretical model and computational frame-
work that allows decomposing distinct patterns of somatic
mutations from a set of cancer samples was developed
[20]. The mathematical model was an extension of the
well-known blind source separation problem, in which
original signals need to be separated from a set of mixed
signals [82], and the algorithm was based on a method
used in face recognition software that allows meaningfully
learning distinct parts of objects [83]. The algorithm
deciphers the minimal set of mutational signatures that
optimally explains the proportion of each mutation type
found in each cancer sample and then the method esti-
mates the contribution of each signature to each cancerwww.sciencedirect.com
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Mutational processes operative in a cancer. This simulated example illustrates four distinct mutational processes with variable strengths operative at
different times throughout the lifetime of the patient. Each of these processes has a unique mutational signature exemplified by the six classes of
somatic substitutions. At the beginning, all mutations in the cell (from which the cancer was eventually developed) were due to the activity of the
endogenous mutational process 1. As time progresses, the other mutational process get activated and the spectrum of the cell continues to change.
Note that the final sequenced cancer genome does not resemble any of the operative mutational signatures.sample (see Ref. [20] for more details about this
method, including a discussion of its limitations).
Initial application of this approach was performed on the
somatic substitutions derived from the whole genomes of
21 breast cancer patients [33]. In order to increase the
resolution of the derived mutational signatures, substi-
tutions were examined using their immediate sequencing
context. This included the base immediately 50 before the
somatic mutation and the base immediately 30 after the
somatic mutation; thus resulting in 96 mutation types —
16 different for each of the six types of somatic substi-
tutions. For example, C > T mutations were extended to
include C > T with (50 adenine): ApCpA, ApCpC,
ApCpG, ApCpT; (50 cytosine): CpCpA, CpCpC, CpCpG,www.sciencedirect.com CpCpT; (50 guanine): GpCpA, GpCpC, GpCpG,
GpCpT; and (50 thymine): TpCpA, TpCpC, TpCpG,
TpCpT. Including the immediate sequence context
allows better differentiation between different muta-
tional processes; for example, distinguishing between
C > T mutations due to the formation UV-light induced
photodimers (i.e. C > T mutations at dipyrimidine sites
such as TpCpC or CpCpC) from C > T mutations due to
deamination of 5-methylcytosine (i.e. C > T mutations at
CpG sites). The mutational catalogues of the 21 breast
cancer genomes were generated, including each of the 96
mutation types, and applying the newly developed
method to these catalogues revealed multiple distinct
mutational signatures of substitutions. As expected, a
mutational signature with features of C > T mutationsCurrent Opinion in Genetics & Development 2014, 24:52–60
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ing the activity of normal endogenous cellular processes.
Further, a mutational signature with C > X mutations at
TpC sites was identified and based on similarity between
its mutational pattern and in vivo experimental data, it
was proposed that this process is due to the activity of the
APOBEC family of deaminases and more specifically
APOBEC1, APOBEC3A, and/or APOBEC3B [84,85].
Additionally, a rather uniform mutational signature (no
prominent features across trinucleotides) was also ident-
ified and, interestingly, the activity of this mutational
signature in each of the 21 samples allowed separation (by
unsupervised hierarchical clustering) of BRCA1 and
BRCA2 wild-type breast tumours from BRCA1 and
BRCA2 germline mutants. Another mutational signature
with unknown aetiology and mutations predominately at
C > G at TpC was also identified. In addition to these
genome-wide signatures, a localized hypermutation
(termed kataegis) was observed in some of the breast
cancer samples. This localized hypermutation was pre-
dominantly constituted of C > T and C > G substitutions
at TpC trinucleotides and it was speculated that it is also
due to the activity of the APOBEC enzymes. Lastly,
deciphering the independent mutational signatures oper-
ative in these breast cancer samples provided the means
for timing their activity across different cancer subclones
[86].
This initial analysis of the mutational signatures operative
in the 21 breast cancer genomes revealed several intri-
guing mutational processes but its focus was predomi-
nantly on substitutions. However, the newly developed
approach for deciphering mutational signatures also
allows extending mutational signature analysis over an
arbitrary selected set of biologically meaningful mutation
types [20]. To demonstrate its applicability, the muta-
tional catalogues of the 21 breast cancer genomes were
extended to include double nucleotide substitutions,
indels at microhomologies, indels at mono/polynucleotide
repeats, and even a complex mutation type such as
kataegis. Reanalysing these mutational catalogues demon-
strated that kataegis separates as its own mutational pro-
cess. Further, double nucleotide substitutions and indels
at microhomologies associated predominantly with the
activity of the previously identified uniform mutational
process. Lastly, indels at mono/polynucleotide repeats
did not strongly associate with any of the previously
described mutational processes [20].
Extending the previously defined mutational catalogues
illustrated the possibility of incorporating additional
mutation types and it revealed some associations between
substitutions and indels thus providing more biological
insight into the identified mutational processes [20].
Further biological insight was derived by analysing muta-
tional catalogues that incorporate the transcriptional
strand on which a substitution resides in the footprintsCurrent Opinion in Genetics & Development 2014, 24:52–60 of a gene. Thus, the previously defined 96 substitution
types were extended to 192 mutation types. For example,
the number of C > T mutations at TpCpA were split into
two categories: the number of C > T mutations at
TpCpA occurring on the untranscribed strand of a gene
and the number of C > T mutations at TpCpA occurring
on the transcribed strand. In general, one would expect
that these two numbers are approximately the same
unless the mutational processes are influenced by activity
of the transcriptional machinery. This could happen, for
example, due to recruitment of the transcription-coupled
component of nucleotide excision repair (NER) [87]. If a
mutational process has a higher number of C > A substi-
tutions on the transcribed strand compared to the C > A
substitutions on the untranscribed strand (i.e. note that
C > A mutations on the untranscribed strand is the same
as G > T mutations on the transcribed strand), this could
indicate that the mutations caused by this process are
being repaired by NER. As such, this analysis provides a
further insight into the operative mutational processes
and their interaction with cellular repair processes. A
known example of such strand bias due to interplay
between a mutational process and a repair mechanism
is the formation of photodimers due to UV-light exposure
that are repaired by NER and result in a higher number of
C > T mutations on the untranscribed strand [87].
Analysing the transcriptional strand bias of the mutational
signatures operative in the 21 breast genomes revealed a
weak strand bias of C > A mutations with unknown
aetiology [20]. Interestingly, deciphering mutational
signatures from 100 breast cancer exomes revealed
exactly the same trinucleotide mutational signatures
but with a different strand bias. Specifically, there was
an elevation of C > X mutations at TpCpT on the tran-
scribed strand of exomes, which was absent in the com-
plete gene footprints derived from the 21 whole genome
sequences [20]. This transcriptional strand bias could be
indicative of exon-specific repair processes that are active
in the cell.
The extensive mutational signature analysis performed
on the 21 breast cancer genomes was recently expanded
and mutational signatures (including substitutions,
indels, dinucleotide substitutions, kataegis, and strand
bias) were deciphered from 30 different types of human
cancer [19]. The previously developed computational
framework was applied to almost five million somatic
mutations identified in 7 042 cancer samples (507 from
whole genome and 6 535 from whole exome sequences).
This included both previously published samples and
newly sequenced whole genomes. The analysis revealed
27 distinct mutational signatures [19]. 22 of these 27
mutational signatures were validated (i.e. confirmed by
orthogonal technologies or other approaches), three were
associated with technology-specific sequencing artefacts,
and two of the mutational signatures remain un-validatedwww.sciencedirect.com
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samples.
This largest cancer genomics analysis to date provided
the first global roadmap describing the signatures of
mutational processes in human cancer. Each of the cancer
types had at least two mutational signatures operative in
it, while some (e.g. cancers of the liver and uterus) had up
to six distinct mutational processes. Remarkably, most of
the cancer samples had at least two mutational signatures
active in them. Aetiology was proposed for 11 of the 22
validated mutational signatures. Two of the mutational
signatures were associated with age of patient at cancer
diagnosis and these signatures were present in 26 of the
30 cancer types and more than 70% of the samples. These
two processes exhibit clear features of C > T at CpG sites
and most likely reflect mutations due to normal cellular
processes (e.g. deamination of 5-methylcytosine, errors
due to DNA replication, and so on) and probably account
for the majority of somatic mutations prior to neoplastic
development.
Based on similarity with in vivo experimental data, two
mutational processes (termed Signature 2 and 13) were
associated with the activity of the APOBEC family of
deaminases. These two signatures exhibit predominantly
C > T and C > G mutations at TpC sites and were
observed in 16 of the 30 cancer types (17% of all
examined cancer samples) [19]. As such, the activity
of these mutational signatures (and respectively the
APOBEC enzymes) is one of the most significant human
carcinogens with prevalence superseding that of tobacco
smoking and exposure to UV light. Recently, further
evidence was provided for the involvement of APO-
BEC3B in human cancers, as its expression was elevated
in tumours compared to their matched normal samples
[88,89].
By comparing the substitution patterns of all signatures
with experimental data, one of the mutational signatures
was associated with exposure to ultraviolet light while
another with benzo[a]pyrene, a known tobacco carcino-
gen. The signature associated with UV-light exhibited a
higher presence of CC > TT dinucleotide substitutions
as well as a strand bias indicative of the formation of
photodimers, which further confirmed the association. In
contrast, a mutational signature associated in lung cancer
exhibited predominantly C > A mutations with a tran-
scriptional strand bias suggesting the formation of bulky
adducts on guanine. Interestingly, this mutational signa-
ture was also associated with CC > AA dinucleotide
substitutions with a strong strand bias. Statistical tests
comparing smokers with non-smokers in two cancer types
(viz. lung adenocarcinoma and tumours of the head and
neck) confirmed a highly significant elevation of this
‘tobacco smoking signature’ in smokers indicating that
it was due to tobacco mutagens.www.sciencedirect.com Further statistical analysis was performed to associate
mutations in genes with the presence of mutational
signatures. Distinct mutational signatures were associated
with: mutations in BRCA1/2 in breast and pancreatic
cancers; failure of the DNA mismatch repair pathway
(e.g. due to methylation of the MLH1 promoter) in
colorectal cancers; hypermutation of the immunoglobulin
gene in CLL; recurring polymerase e mutations in uterine
and colorectal cancers. Interestingly, the mutational sig-
nature associated with failure of DNA mismatch repair
was observed in nine different cancer types. While this
process was operative in 20% of colorectal cancers and
15% of uterine cancers, it was also found in at least 1% of
cancer samples in another seven cancer types. Another
interesting observation was that while almost all BRCA1/
2 mutants exhibit a specific mutational signature, there
were also BRCA1/2 wild-type samples with high number
of mutations due to this mutational process. Thus, it is
possible that some BRCA1/2 wild-type samples might
harbour somatic mutations or other abnormalities that
result in a failure of homologous repair and activation
of this mutational process.
Chemotherapy treatment could cause its own set of
somatic mutations [24]. Examining the pre-treatment
history of all 7 042 cancer samples revealed that melano-
mas and glioblastomas pre-treated with an alkylating
agent exhibit a distinct mutational signature.
The performed global analysis was able to propose an
association for 11 of the 22 validated mutation signatures,
while the origins and aetiology of the other 11 mutational
signatures remains unknown. Lastly, this study also
examined the presence of loci of kataegis across human
cancer and it revealed that kataegis is not confined only to
breast cancer but it is also present in at least another seven
cancer types including pancreas, lung, liver, medulloblas-
toma, CLL, B-cell lymphomas, and ALL.
Conclusions and future promises
In the past five decades, analysis of mutational patterns
has evolved from in vitro observation of DNA changes
caused by ultraviolet light, to examination of the muta-
tional spectra generated by sequencing single cancer
genes in multiple samples, to performing targeted capil-
lary sequencing screens of multiple genes across hun-
dreds of samples, and more recently to large-scale analysis
of the genomes of thousands of cancer patients revealing
the signatures of the mutational processes involved in the
development of their tumours. In the next decade, thou-
sands of new whole cancer genomes across the majority of
cancer types [26] will be generated, which will allow the
creation of a final and comprehensive map of mutational
signatures. The generation of such a mutagenesis map
will most likely require the refinement of existing math-
ematical methods to accurately examine all known types
of somatic mutations: substitutions, indels, copy numberCurrent Opinion in Genetics & Development 2014, 24:52–60
58 Cancer genomicsvariations, structural rearrangements, and potentially
even epigenetic changes. These analyses of next gener-
ation sequencing data must be complemented with
experimental work revealing the aetiology of the ident-
ified mutational processes.
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